Document is current
Any future updates will be listed below
-
Authors
Hu, Xichun https://orcid.org/0000-0001-6148-9186
Zhang, Qingyuan
Wang, Leiping
Zhang, Jian
Ouyang, Quchang
Wang, Xiaojia
Li, Wei
Xie, Weimin
Tong, Zhongsheng
Wang, Shusen https://orcid.org/0000-0003-0139-5780
Xu, Faliang
Sun, Tao
Liu, Wei
Chen, Zhendong
Wu, Jinsheng
Wang, Ying
Wang, Haixia
Yan, Min
Wang, Xinshuai
Wang, Jingfen
Cao, Feilin
Du, Yingying
Zhang, Yongqiang
Chen, Lilin
Lu, Ping
Sun, Sanyuan
Zhang, Ruiwen
Zang, Aimin
Nie, Xiuqing
Lei, Yuan
- License Information
-
More Information
Article History
Received: 1 September 2024
Revised: 6 January 2025
Accepted: 16 January 2025
First Online: 17 February 2025
Competing interests
: X.C.H. reports receiving advisory fees from AstraZeneca, Roche, and Hengrui. X.Q.N. and Y.L. are employees of NovoCodex Biopharmaceuticals Co., Ltd. All other authors declare no competing interests.
